Therapy Areas: Central Nervous System
Translate Bio Names Barbier as CMO
7 November 2017 - - US-based biotechnology company Translate Bio has appointed Ann Barbier, M.D., Ph.D., as chief medical officer, effective immediately, the company said.
Barbier brings nearly 20 years of drug discovery and development experience to Translate Bio, and will be responsible for leading all clinical research and development, medical affairs, and related functions at Translate Bio.
Prior to joining Translate Bio, Barbier was vice president of clinical development, rare genetic diseases, at Agios Pharmaceuticals, where she led the development program of a small molecule in rare benign hematological diseases.
Previously, Barbier spent seven years at Shire, most recently as global clinical development lead and senior medical director, where she worked on a variety of rare genetic diseases including lysosomal storage diseases and hereditary angioedema. Her prior experience includes positions at Envivo, Johnson and Johnson and Aventis.
During her career, Barbier has made significant contributions to several approved products such as Elaprase (Hunter syndrome), Aubagio (multiple sclerosis) and Firazyr (hereditary angioedema), and has led several investigational new drug applications for new chemical entities.
Barbier received her M.D. and Ph.D. in pharmacology from the University of Gent, Belgium, and a Master of Science from the Free University of Brussels, Belgium. She pursued a postdoctoral fellowship at the University of Tennessee in Memphis.
Translate Bio is focused on the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases.
The company's RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases caused by insufficient protein production, including rare diseases of the liver, lung, and central nervous system.
Login
Username:

Password: